Outcomes of Embryos Created From Abnormally Fertilized Oocytes
June 22, 2026 updated by: Inception Fertility Research Institute, LLC
The purpose of this study is to retrospectively analyze data from multiple clinics in a fertility network on embryos that were created from abnormally fertilized oocytes (AFO) including the rate of transfers and any clinical outcomes in order to inform providers in their decision making regarding AFOs.
Study Overview
Status
Not yet recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
92
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Laurel Anderson, BS
- Phone Number: 3463621476
- Email: landerson@inceptionllc.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Females of varying age, race, and ethnicity who underwent in vitro fertilization which resulted in a blastocyst derived from an abnormally fertilized embryo
Description
Inclusion Criteria:
- Underwent in vitro fertilization which resulted in a blastocyst derived from an abnormally fertilized embryo
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Outcomes
Time Frame: From embryo transfer to delivery
|
For blastocysts derived from AFOs that were transferred, clinical outcomes include implantation rate, ongoing pregnancy rate, live birth rate, and spontaneous abortion rate.
|
From embryo transfer to delivery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Canon C, Thurman A, Li A, Hernandez-Nieto C, Lee JA, Roth RM, Slifkin R, Briton-Jones C, Stein D, Copperman AB. Assessing the clinical viability of micro 3 pronuclei zygotes. J Assist Reprod Genet. 2023 Jul;40(7):1765-1772. doi: 10.1007/s10815-023-02830-y. Epub 2023 May 25.
- Hondo S, Arichi A, Muramatsu H, Omura N, Ito K, Komine H, Monzen S, Mukai N, Endo M, Katase S, Kidera N, Sasaki H, Koi H, Yorimitsu T, Ohara M, Kawamura T, Shimizu Y. Clinical outcomes of transfer of frozen and thawed single blastocysts derived from nonpronuclear and monopronuclear zygotes. Reprod Med Biol. 2019 May 15;18(3):278-283. doi: 10.1002/rmb2.12275. eCollection 2019 Jul.
- Kemper JM, Liu Y, Afnan M, Mol BWJ, Morbeck DE. What happens to abnormally fertilized embryos? A scoping review. Reprod Biomed Online. 2023 May;46(5):802-807. doi: 10.1016/j.rbmo.2023.02.005. Epub 2023 Feb 22.
- Al Hashimi B, Harvey SC, Harvey KE, Linara-Demakakou E, Raikundalia B, Green O, Griffin DK, Ahuja K, Macklon N. Reassessing the conventional fertilization check: leveraging preimplantation genetic testing for aneuploidy to increase the number of transferrable embryos. Reprod Biomed Online. 2025 Jun;50(6):104595. doi: 10.1016/j.rbmo.2024.104595. Epub 2024 Oct 24.
- Mutia K, Wiweko B, Iffanolida PA, Febri RR, Muna N, Riayati O, Jasirwan SO, Yuningsih T, Mansyur E, Hestiantoro A. The Frequency of Chromosomal Euploidy Among 3PN Embryos. J Reprod Infertil. 2019 Jul-Sep;20(3):127-131.
- Girardi L, Patassini C, Miravet Valenciano J, Sato Y, Fagundes Cagnin N, Castellon JA, Cogo F, Zambon P, Blesa D, Jimenez Almazan J, Akinwole A, Coprerski B, Rubio C. Incidence of haploidy and triploidy in trophectoderm biopsies of blastocysts derived from normally and abnormally fertilized oocytes. J Assist Reprod Genet. 2024 Dec;41(12):3357-3370. doi: 10.1007/s10815-024-03278-4. Epub 2024 Oct 8.
- Ezoe K, Takahashi T, Shimazaki K, Miki T, Tanimura Y, Amagai A, Sawado A, Akaike H, Mogi M, Kaneko S, Kato M, Kato K, Tarozzi N, Borini A, Coticchio G. Human 1PN and 3PN zygotes recapitulate all morphokinetic events of normal fertilization but reveal novel developmental errors. Hum Reprod. 2022 Sep 30;37(10):2307-2319. doi: 10.1093/humrep/deac177.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2026
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
June 1, 2027
Study Registration Dates
First Submitted
June 1, 2026
First Submitted That Met QC Criteria
June 22, 2026
First Posted (Actual)
June 24, 2026
Study Record Updates
Last Update Posted (Actual)
June 24, 2026
Last Update Submitted That Met QC Criteria
June 22, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRI-AFO-2026-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.